Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Henegar

Physician Assistant, Medical Georgetown, KY Physician Assistant

NPI 1659623817 CMS profile 10553406

1140 Lexington Rd, Georgetown, KY 40324

Open in the dashboard

General payments

$9,507

396 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Henegar of Georgetown, KY is reported in the CMS Open Payments database as having received $9,507 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,460 105
2024 General $3,185 112
2023 General $2,239 107
2022 General $844 35
2021 General $779 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Henegar
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ashley Henegar were reported at $2,460. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ashley Henegar Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $779 $156 $41–$563 $132
2022 $844 $185 $55–$649 $149
2023 $2,239 $199 $58–$717 $160
2024 $3,185 $206 $62–$740 $164
2025 $2,460 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,592 57 payments
  2. Janssen Biotech, Inc. $740 30 payments
  3. Astellas Pharma US Inc $719 30 payments
  4. Seattle Genetics, Inc. $707 12 payments
  5. Pfizer Inc. $673 29 payments
  6. Eisai Inc. $490 10 payments
  7. E.R. Squibb & Sons, L.L.C. $432 26 payments
  8. Daiichi Sankyo Inc. $403 14 payments
  9. AstraZeneca Pharmaceuticals LP $293 15 payments
  10. Regeneron Healthcare Solutions, Inc. $277 10 payments
  11. Other $3,182 163 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,312 372 payments
  2. Education $1,398 16 payments
  3. Long term medical supply or device loan $798 8 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,255 35 payments
  2. Lenvima $490 10 payments
  3. XTANDI $487 25 payments
  4. REBLOZYL $352 14 payments
  5. ENHERTU $280 9 payments
  6. LIBTAYO $277 10 payments
  7. KEYTRUDA $263 12 payments
  8. OPDIVO $243 19 payments
  9. TALZENNA $224 11 payments
  10. ERLEADA $223 7 payments
  11. Other $6,164 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

234

Median for Physician Assistant: 241

Drug cost

$236,300

Median for Physician Assistant: $4,110

Branded share of claims

33.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brukinsa Zanubrutinib Brand 12 $184,408
Eliquis Apixaban Brand 51 $35,401
Xarelto Rivaroxaban Brand 16 $14,152
Potassium Chloride Generic 59 $962
Ondansetron Hcl Generic 18 $961
Anastrozole Generic 31 $245
Hydroxyurea Generic 24 $84
Dexamethasone Generic 11 $57
Prednisone Generic 12 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$35,726

Of which drugs: $87

Medicare patients

168

Average age 73

Services billed

837

83 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Chronic kidney disease 38%
Diabetes 36%
Cancer 35%
Ischemic heart disease 33%
COPD 30%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 93 $87

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 49 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $884
$884 — —
ERLEADA
  • Janssen Biotech, Inc. $184
$184 — —
Lenvima
  • Eisai Inc. $174
$174 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $107
$107 — —
ONIVYDE
  • Ipsen Biopharmaceuticals, Inc $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 49 with Patron

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record